In a report released on March 21, David Evans from Kepler Capital maintained a Buy rating on Novartis AG (NOVN – Research Report), with a ...

Novartis was announced as an official partner of this year’s Eurovision competition last fall, after the song entry from ...

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...

ZURICH (Reuters) -Swiss drugmaker Novartis is ending its use of diverse panels for all of its hiring in the United States, the company told Reuters on Wednesday, citing the changing legal and policy ...

ZURICH (Reuters) -Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its ...

Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG (NOVN – Research Report) on March 17 and set a price target of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

NEW YORK (Reuters) -The National Football League has signed its first-ever pharmaceutical partner in a multi-year deal with ...